Regeneron Pharmaceuticals
REGN
1,245 hedge funds and large institutions have $49B invested in Regeneron Pharmaceuticals in 2025 Q3 according to their latest regulatory filings, with 173 funds opening new positions, 487 increasing their positions, 419 reducing their positions, and 111 closing their positions.
75% more funds holding in top 10
Funds holding in top 10: 12 → 21 (+9)
56% more first-time investments, than exits
New positions opened: 173 | Existing positions closed: 111
44% more call options, than puts
Call options by funds: $1.5B | Put options by funds: $1.04B
16% more repeat investments, than reductions
Existing positions increased: 487 | Existing positions reduced: 419
4% more funds holding
Funds holding: 1,202 → 1,245 (+43)
4% more capital invested
Capital invested by funds: $46.9B → $49B (+$2.06B)
0.51% less ownership
Funds ownership: 84.12% → 83.61% (-0.51%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Dodge & Cox
San Francisco,
California
|
+$410M |
| 2 |
AQR Capital Management
Greenwich,
Connecticut
|
+$343M |
| 3 |
Invesco
Atlanta,
Georgia
|
+$231M |
| 4 |
Nuveen
Charlotte,
North Carolina
|
+$189M |
| 5 |
Caisse de Depot et Placement du Quebec (CDPQ)
Montreal,
Quebec, Canada
|
+$140M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital International Investors
Los Angeles,
California
|
-$1.29B |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$787M |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$255M |
| 4 |
BlackRock
New York
|
-$248M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
-$212M |
REGN Hedge Fund Activity: Q3 2025 in Review
1,245 of the 7,640 institutional investors tracked by Wall St. Rank reported a position in Regeneron Pharmaceuticals (REGN) for Q3 2025, worth a combined $49B — up 4.4% from $46.9B a quarter earlier.
Buyers outnumbered sellers: 173 funds opened new REGN positions and 111 closed out — a net gain of 62 holders — while 487 added to existing stakes and 419 trimmed.
The largest buyer was Dodge & Cox, adding an estimated $410M. The largest seller was Capital International Investors, cutting an estimated $1.29B.
- 1,245 institutional investors held Regeneron Pharmaceuticals (REGN) as of Q3 2025, up from 1,202 in Q2 2025.
- Funds reported $49B of Regeneron Pharmaceuticals stock for Q3 2025, up 4.4% quarter-over-quarter.
- 173 funds opened new Regeneron Pharmaceuticals positions in Q3 2025 and 111 closed out, a net change of +62 holders.
- The largest Regeneron Pharmaceuticals buyer in Q3 2025 was Dodge & Cox, an estimated $410M added.
- The largest Regeneron Pharmaceuticals seller in Q3 2025 was Capital International Investors, an estimated $1.29B sold.
Based on aggregated 13F filings for Q3 2025.